Interferon alfa-2b
information and resources from the National Cancer Institute
Intron A Schering Corp Jun 21 2002
Intron A Schering Corp Jun 21 2002
Intron A Intron A Schering Corp Jun 21 2002
Intron A
Interferon alfa-2b, recombinant for injection is indicated as adjuvant to surgical treatment in patients 18 years of age or older with malignant melanoma who are free of disease but at high risk for systemic recurrence within 56 days of surgery.
Schering Corp Nov 06 1997
Intron A
Interferon alfa-2b, recombinant for Injection is indicated for intralesional treatment of selected patients 18 years of age or older with condylomata acuminata involving external surfaces of the genital and perianal areas.
Schering Corp Nov 06 1997
Intron A
Interferon alfa-2b, recombinant for Injection is indicated for the initial treatment of clinically aggressive follicular Non-Hodgkin’s Lymphoma in conjunction with anthracycline-containing combination chemotherapy in patients 18 years of age or older.
Schering Corp Nov 06 1997
Intron A
Interferon alfa-2b, recombinant for Injection is indicated for the treatment of chronic hepatitis B in patients 18 years of age or older with compensated liver disease and HBV replication.
Schering Corp Nov 06 1997
Intron A
Interferon alfa-2b, recombinant for Injection is indicated for the treatment of chronic hepatitis C in patients 18 years of age or older with compensated liver disease who have a history of blood or blood-product exposure and/or are HCV antibody positive.
Schering Corp Nov 06 1997
Intron A
Interferon alfa-2b, recombinant for Injection is indicated for the treatment of patients 18 years of age or older with hairy cell leukemia.
Schering Corp Nov 06 1997
Intron A
Interferon alfa-2b, recombinant for Injection is indicated for the treatment of selected patients 18 years of age or older with AIDS-Related Kaposi's Sarcoma. The likelihood of response to INTRON A therapy is greater in patients who are without systemic symptoms, who have limited lymphadenopathy and who have a relatively intact immune system as indicated by total CD4 count.
Schering Corp Nov 06 1997
|
|
|
|
news articles
Hepatitis C Treatment for People With Severe Mental Illness Feb 28, 2006
Psychosomatics (subscription) Manns M, McHutchinson J, Gordon S, et al: PEG-interferon alfa-2B plus ribavirin compared with interferon alfa-2B plus ribavirin for initial treatment of ...
Human Genome Sciences Announces Positive Interim Results of Phase ... Mar 14, 2006
PR Newswire (press release), Interim (week 12) Phase 2b virological efficacy and safety results of albumin interferon alfa-2b combined with ribavirin in genotype 1 chronic hepatitis C ...
Idenix Announces Thirteen Data Presentations at the 2006 European ... Mar 17, 2006
PR Newswire (press release), Dr. Xiao-Jian Zhou, Idenix's Associate Director, Clinical Pharmacology, will present "Absence of Effect of Pegylated Interferon Alfa-2b on the Pharmacokinetics ...
SP rises on deal and analyst upgrades Mar 21, 2006
Pharma Times (subscription), ...since the demise of Rebetol (ribavirin) to generic competition and with increasing rivalry seen for its newer offering Peg-Intron (peg-interferon alfa 2b). ...
Healthcare: At a Glance - Roche Hepatitis Drug Thrust Onto Front ... Mar 3, 2006
International News Service, GlaxoSmithKline's Epivir (lamivudine) is the best-known product in this disease area, although Schering-Plough's Intron A (interferon alfa-2b) is also used to ...
Three Rivers Pharmaceuticals Announces FDA Final Approval of ... Dec 5, 2005
PR Newswire (press release), B cholesteryl sulfate complex for injection) worldwide and Ribasphere(R) (ribavirin capsules), 200 mg for use in combination with interferon alfa-2b in the US.
|
|
